RECRUITING Phase 3 ClinicalTrials.gov

Stop Transmission of Gambiense Human African Trypanosomiasis

Sponsor: Institute of Tropical Medicine, Belgium • ClinicalTrials.gov ID: NCT07789743

Registry updated: 2026-08-27

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This protocol describes both the epidemiological study which aims at assessing whether over a three-year period a zero prevalence can be achieved when implementing a screen \& treat approach with acoziborole, as well as a nested clinical study aimed at generating further evidence on safety of acoziborole in gambiense human African trypanosomiasis (gHAT) seropositives individuals. The overall coordinator will be ITM. ITM will be fully responsible for the epidemiological study (study Part A), including cost effectiveness and evaluation of diagnostic tests. DNDi will be the legal sponsor of the nested safety clinical study (study Part B) and will ensure compliance with regulatory requirements and good clinical practices (GCP) for this part of the study. We hypothesize that by systematically screening the populations of all endemic villages in a well-defined HAT focus and by expanding gHAT treatment to all seropositives, we will be able to arrive at a zero prevalence over a three-year period. The objectives are to evaluate whether a strategy based on widened treatment for all parasitologically negative seropositive gHAT suspects with acoziborole can lead to interruption of transmission of T.b.gambiense in a mainland focus and to assess the safety of acoziborole in gHAT seropositve individuals and parasitologically negative.

Interventions

Acoziborole (Drug)
treatment of seropositive individuals (positive serology test, but parasitology not confirmed). Subjects agreeing to participate study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post-treatment.

Eligibility criteria

Inclusion Criteria: * Participants able to give signed informed consent and assent form for adolescents, which includes willingness to comply with the schedule of follow-up visits and other requirements and restrictions listed in the informed consent form (ICF) and in this protocol * All sexes * 11 years of age or older at the start of the study and weight ≥30 kg at the screening of Part B * Participants who are CATT test or HAT RDT positive (information provided by the mobile team and included into TrypElim (see Part A) * Participants who are able to ingest oral tablets * Participants with known address and/or contact details provided * Participants who are able to comply with the schedule of follow-up visits and other requirements of the study * Participants must agree not take part in any other clinical trials during the participation in part B of this study * Participants of child-bearing potential must be willing to use appropriate contraceptive methods. Exclusion Criteria: * Individuals with a positive parasitological exam on the spot at baseline (mAECT or lymph gland puncture) * Participants previously treated for g-HAT or previously treated because of gHAT seropositive results * Pregnant women * Breast-feeding women * Children ≥11 years, but under 30kg body weight at the screening for part B * Clinically significant medical condition that could, in the opinion of the investigator, jeopardise the subject's safety or participation in the study * Individuals presenting a jaundice at screening * Participants who are taking, or who are expected to need to start within 3 months, a medicine (including traditional or herbal) which may interact with acoziborole and which cannot be stopped or adjusted (please refer to investigator manual or contact DNDi)

Conditions

Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense

Locations

Coordination Provincial de Lutte contre la THA — Bwamanda, Democratic Republic of the Congo

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment